ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2025
ImmuCell Corporation (Nasdaq: ICCC), an animal health company focused on dairy and beef cattle products, will announce its Q2 2025 financial results after market close on August 14, 2025. The company will host a conference call on August 15, 2025, at 9:00 AM ET to discuss the results.
ImmuCell manufactures First Defense庐, providing Immediate Immunity鈩� to newborn dairy and beef calves, and is developing 搁别-罢补颈苍庐, a novel treatment for subclinical mastitis in dairy cows without FDA-required milk discard or pre-slaughter withdrawal restrictions.
ImmuCell Corporation (Nasdaq: ICCC), un'azienda nel settore della salute animale specializzata in prodotti per bovini da latte e da carne, annuncer脿 i suoi risultati finanziari del secondo trimestre 2025 dopo la chiusura del mercato il 14 agosto 2025. La societ脿 terr脿 una conference call il 15 agosto 2025 alle 9:00 AM ET per discutere i risultati.
ImmuCell produce First Defense庐, che offre Immediate Immunity鈩� ai vitelli neonati da latte e da carne, e sta sviluppando 搁别-罢补颈苍庐, un trattamento innovativo per la mastite subclinica nelle vacche da latte senza restrizioni di scarto del latte o ritiro pre-macellazione richieste dalla FDA.
ImmuCell Corporation (Nasdaq: ICCC), una empresa de salud animal enfocada en productos para ganado lechero y de carne, anunciar谩 sus resultados financieros del segundo trimestre de 2025 despu茅s del cierre del mercado el 14 de agosto de 2025. La compa帽铆a realizar谩 una conferencia telef贸nica el 15 de agosto de 2025 a las 9:00 AM ET para discutir los resultados.
ImmuCell fabrica First Defense庐, que proporciona Immediate Immunity鈩� a terneros reci茅n nacidos de ganado lechero y de carne, y est谩 desarrollando 搁别-罢补颈苍庐, un tratamiento novedoso para la mastitis subcl铆nica en vacas lecheras sin las restricciones de descarte de leche o retiro pre-sacrificio requeridas por la FDA.
ImmuCell Corporation (Nasdaq: ICCC)電� 雮欕啀 氚� 鞙§毎鞖� 臧�於� 鞝滍拡鞐� 欷戩爯鞚� 霊� 霃欕 瓯搓皶 須岇偓搿�, 2025雲� 2攵勱赴 鞛 瓴瓣臣毳� 2025雲� 8鞗� 14鞚� 鞛� 毵堦皭 頉� 氚滍憸頃� 鞓堨爼鞛呺媹雼�. 須岇偓電� 2025雲� 8鞗� 15鞚� 鞓れ爠 9鞁�(霃欕秬 響滌鞁�)鞐� 瓴瓣臣毳� 雲检潣頃橁赴 鞙勴暅 旎嵓霟办姢 旖滌潉 臧滌禍頃╇媹雼�.
ImmuCell鞚� 鞁犾儩 雮欕啀 氚� 鞙§毎 靻§晞歆�鞐愱矊 Immediate Immunity鈩㈦ゼ 鞝滉车頃橂姅 First Defense庐毳� 鞝滌“頃橂┌, FDA 鞖旉惮 靷暛鞚� 鞖办湢 韽愱赴雮� 霃勳稌 鞝� 鞝滍暅 鞐嗢澊 雮欕啀 鞎旍唽鞚� 鞛犽车 鞙犾劆鞐� 旃橂毳� 鞙勴暅 順侅嫚鞝侅澑 旃橂鞝� 搁别-罢补颈苍庐鞚� 臧滊皽 欷戩瀰雼堧嫟.
ImmuCell Corporation (Nasdaq : ICCC), une entreprise sp茅cialis茅e dans la sant茅 animale avec un focus sur les produits pour bovins laitiers et 脿 viande, annoncera ses r茅sultats financiers du deuxi猫me trimestre 2025 apr猫s la cl么ture des march茅s le 14 ao没t 2025. La soci茅t茅 tiendra une conf茅rence t茅l茅phonique le 15 ao没t 2025 脿 9h00 ET pour discuter des r茅sultats.
ImmuCell fabrique First Defense庐, offrant Immediate Immunity鈩� aux veaux nouveau-n茅s laitiers et 脿 viande, et d茅veloppe 搁别-罢补颈苍庐, un traitement innovant pour la mammite subclinique chez les vaches laiti猫res sans les restrictions de rejet de lait ou de retrait pr茅-abattage exig茅es par la FDA.
ImmuCell Corporation (Nasdaq: ICCC), ein Unternehmen im Bereich Tiergesundheit mit Fokus auf Produkte f眉r Milch- und Rindfleischrinder, wird seine Finanzergebnisse f眉r das zweite Quartal 2025 nach B枚rsenschluss am 14. August 2025 bekannt geben. Das Unternehmen wird am 15. August 2025 um 9:00 Uhr ET eine Telefonkonferenz abhalten, um die Ergebnisse zu besprechen.
ImmuCell stellt First Defense庐 her, das Neugeborenen von Milch- und Fleischrindern Immediate Immunity鈩� bietet, und entwickelt 搁别-罢补颈苍庐, eine neuartige Behandlung der subklinischen Mastitis bei Milchk眉hen ohne von der FDA vorgeschriebene Milchverwerfung oder Vor-Schlacht-R眉ckzugsfristen.
- None.
- None.
Conference Call Scheduled for Friday, August 15, 2025 at 9:00 AM ET
PORTLAND, Maine, Aug. 07, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq:听ICCC) (鈥淚mmuCell鈥� or the 鈥淐ompany鈥�), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, expects to report unaudited financial results for the quarter ended June 30, 2025 after the market closes on Thursday, August 14, 2025.
The Company is planning to host a conference call the next morning, Friday, August 15, 2025, at 9:00 AM ET to review the unaudited financial results. Interested parties can access the conference call by dialing (844) 855-9502 (toll free) or (412) 317-5499 (international) at 9:00 AM ET. A teleconference replay of the call will be available until August 22, 2025 at (877) 344-7529 (toll free) or (412) 317-0088 (international), utilizing replay access code #5659118.
The Company anticipates no change to the preliminary sales results for the second quarter ended June 30, 2025 that were disclosed on July 9, 2025. The Company expects to file its Quarterly Report on Form 10-Q on Thursday, August 14, 2025 after the market closes.
Investors are encouraged to review the Company鈥檚 updated Corporate Presentation slide deck that provides an overview of the Company鈥檚 business which can be accessed under the 鈥淚nvestors鈥� tab of the Company鈥檚 website at , or by request to the Company. An updated version of the slide deck will be made available after the market closes on Thursday, August 14, 2025.
About ImmuCell:
ImmuCell Corporation's (Nasdaq: ICCC) purpose is to create scientifically proven and practical products that improve the health and productivity of dairy and beef calves.听 ImmuCell manufactures and markets First Defense庐, which provides Immediate Immunity鈩� to newborn dairy and beef calves, and is developing Re-Tain庐, a novel treatment for subclinical mastitis in dairy cows without FDA-required milk discard or pre-slaughter withdrawal label restrictions that provides an alternative to traditional mastitis antibiotics. Press releases and other information about the Company are available at: .
| Contacts: | Michael F. Brigham, President and CEO 听听听听听听听听听听听听听听听听听听听听听听 Timothy C. Fiori, Chief Financial Officer 听听听听听听听听听听听听听听听听听听听听听听听听听听 ImmuCell Corporation 听听听听听听听听听听听听听听听听听听听听听听 (207) 878-2770听听 |
| 听 | 听 |
| 听 | Joe Diaz, Robert Blum and Joe Dorame 听听听听听听听听听听听听听 Lytham Partners, LLC 听听听听听听听听听听听听听听 (602) 889-9700 听听听听听听听听听听听听听听听听听听听听听听听听听听 [email protected] |
听听听听 听 听 听 听 听 听听
听听听听听听听听听听听听
听 听 听 听 听 听 听 听 听 听 听 听 听 听
FAQ
When will ImmuCell (ICCC) release Q2 2025 earnings?
How can investors join ImmuCell's Q2 2025 earnings call?
What products does ImmuCell (ICCC) manufacture?
Where can investors access ImmuCell's corporate presentation?
